Multiple Sclerosis (ICD-11: 8A40) - Complete Coding and Diagnostic Guide

1. Introduction

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination, axonal loss, and progressive neurodegeneration. It is an autoimmune condition in which the immune system attacks the myelin sheath that covers neurons, causing irreversible damage to nerve tissue. The disease predominantly affects young adults, with typical onset between 20 and 40 years of age, being more frequent in women than in men, at an approximate ratio of 2-3:1.

Multiple sclerosis represents a significant challenge for public health systems worldwide due to its chronic, disabling nature and the high cost of disease-modifying treatments. It is estimated that millions of people live with MS globally, with variable prevalence according to geographic latitude - being more common in regions distant from the Equator. The disease is one of the leading causes of non-traumatic neurological disability in young adults, profoundly impacting quality of life, work capacity, and functional independence of patients.

Correct coding of multiple sclerosis using the ICD-11 code 8A40 is fundamental for various aspects of clinical and administrative management. Accurate coding enables appropriate epidemiological tracking, facilitates clinical research, ensures appropriate reimbursement for services provided, guarantees access to high-cost medications, and enables public health policy planning based on reliable data. Furthermore, correct documentation is essential for justifying work absences, granting disability benefits, and enabling appropriate longitudinal follow-up of patients.

2. Correct ICD-11 Code

Code: 8A40

Description: Multiple sclerosis

Parent category: Multiple sclerosis or other diseases of the white matter

Official definition: The diagnosis of MS should be established based on clinical criteria, with support from imaging studies and other paraclinical examinations. The clinical phenotype can be evaluated based on current status and historical clinical and paraclinical data, with the understanding that this may be a dynamic process and that the subtype at initial evaluation may change over time.

This definition emphasizes fundamental aspects of multiple sclerosis diagnosis. First, it highlights that the diagnosis is essentially clinical, based on the patient's symptomatic presentation and disease evolution over time. Second, it recognizes the importance of complementary examinations, particularly brain and spinal cord magnetic resonance imaging, which demonstrate characteristic demyelination lesions. Third, and perhaps most importantly, it recognizes the dynamic nature of the disease - the clinical phenotype may evolve from relapsing-remitting forms to secondary progressive forms, requiring periodic reassessment of classification.

The code 8A40 serves as a parent code for various specific subtypes of multiple sclerosis, allowing for more detailed classification when appropriate. The hierarchical structure of ICD-11 makes it possible to code both the general condition and its specific manifestations, facilitating both detailed clinical documentation and broader epidemiological analyses.

3. When to Use This Code

Code 8A40 should be used in specific clinical situations where the diagnosis of multiple sclerosis has been established according to validated diagnostic criteria. Below are detailed practical scenarios:

Scenario 1: Patient with recurrent episodes of neurological symptoms A 28-year-old woman presents with a history of two distinct episodes of neurological symptoms separated by at least 30 days. The first episode consisted of unilateral optic neuritis with visual loss and pain on eye movement, with complete recovery after four weeks. Six months later, she developed ascending paresthesias in the lower limbs and difficulty urinating, lasting three weeks. Brain magnetic resonance imaging demonstrates multiple hyperintense lesions on T2 in the periventricular and juxtacortical white matter, some with contrast enhancement. Cerebrospinal fluid analysis revealed oligoclonal bands absent in serum. This case meets criteria for relapsing-remitting MS, justifying the use of code 8A40.

Scenario 2: Diagnosis established by revised McDonald criteria A 35-year-old man presents with an acute episode of diplopia and cerebellar ataxia. Initial brain magnetic resonance imaging shows demyelinating lesions disseminated in space (periventricular, juxtacortical, infratentorial, and spinal lesions) and in time (lesions with and without contrast enhancement simultaneously). Although this is the first clinical episode, the criteria for dissemination in space and time are satisfied by imaging, establishing the diagnosis of MS. Code 8A40 is appropriate even in the absence of multiple clinical relapses.

Scenario 3: Patient with insidious progression of disability A 45-year-old female patient reports gradual worsening of gait over two years, without clearly defined relapses. She presents with progressive spasticity in the lower limbs, hyperreflexia, and bilateral Babinski sign. Magnetic resonance imaging demonstrates multiple lesions in cerebral white matter and spinal cord atrophy. Cerebrospinal fluid shows intrathecal synthesis of immunoglobulins. This presentation is compatible with primary progressive MS, using code 8A40 with appropriate specifier.

Scenario 4: Patient under follow-up with established diagnosis A 32-year-old patient with a diagnosis of MS for five years, currently on disease-modifying therapy, presents for routine consultation. Even in the absence of new relapses or progression, code 8A40 should be used in all follow-up visits, rehabilitation procedures, examination requests, and prescriptions for medications related to the condition.

Scenario 5: Documentation for work leave or benefits A patient with established MS develops a severe relapse with paraparesis and requires work leave for three months for treatment with corticosteroids and rehabilitation. Code 8A40 is essential in medical documentation to justify the leave, the need for intensive treatment, and possible granting of temporary or permanent disability benefits.

Scenario 6: Conversion from clinically isolated syndrome to MS A patient who had been previously diagnosed with clinically isolated syndrome (code 8A41) develops a second clinical relapse two years after the initial event, confirming the diagnosis of MS. The coding should be updated from 8A41 to 8A40, reflecting the evolution of the clinical presentation and the definitive fulfillment of diagnostic criteria.

4. When NOT to Use This Code

There are specific situations where code 8A40 should not be applied, even when there are neurological symptoms or imaging findings suggestive of demyelination:

Clinically isolated syndrome (CIS): When the patient presents with only one episode of neurological symptoms suggestive of demyelination, but does not meet complete criteria for dissemination in time, code 8A41 (Isolated demyelinating syndromes of the central nervous system) should be used. Although CIS may represent the first manifestation of MS, until complete diagnostic criteria are satisfied, the most appropriate coding is 8A41.

Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD): These conditions present clinical and radiological features that may overlap with MS, but represent distinct entities with different pathophysiology, treatment, and prognosis. The presence of anti-aquaporin-4 or anti-MOG antibodies, longitudinally extensive spinal cord lesions (three or more vertebral segments), preferential involvement of optic nerves and area postrema, and absence of typical MS brain lesions favor the diagnosis of NMO/NMOSD, which should be coded as 8A43.

Acute disseminated encephalomyelitis (ADEM): This is a monophasic demyelinating event, usually post-infectious or post-vaccinal, more common in children. It is characterized by acute onset of multifocal neurological symptoms, encephalopathy, diffuse and large demyelinating lesions on magnetic resonance imaging, and monophasic course without recurrences. It should be coded as 8A42, not as MS.

Demyelinating lesions secondary to other conditions: White matter lesions may occur in various conditions unrelated to MS, including cerebrovascular disease, migraine, vasculitis, infectious diseases (such as neurosyphilis or HIV), leukodystrophies, and normal aging. The presence of lesions on magnetic resonance imaging is not sufficient for the diagnosis of MS without appropriate clinical correlation and exclusion of alternative diagnoses.

Unconfirmed diagnostic suspicion: When there is clinical suspicion of MS, but investigation is still ongoing and diagnostic criteria have not been completely satisfied, specific symptom codes (such as visual disturbances, sensory changes, muscle weakness) should be used instead of 8A40, avoiding premature diagnosis with significant implications for the patient.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of multiple sclerosis is primarily based on the revised McDonald criteria, which require evidence of dissemination in space and time of demyelinating lesions. To confirm the diagnosis:

Clinical evaluation: Perform detailed history taking investigating previous episodes of neurological symptoms, even if they were not valued at the time. Question about optic neuritis, diplopia, vertigo, sensory changes, muscle weakness, bladder or bowel dysfunction, fatigue, and cognitive symptoms. Document the duration of episodes, pattern of evolution (relapses with recovery or continuous progression), and degree of recovery.

Neurological examination: Perform complete neurological examination identifying objective signs of central nervous system dysfunction, including alterations of cranial nerves, muscle strength, sensation, coordination, deep reflexes, pathological reflexes, and gait.

Magnetic resonance imaging: Request brain and spinal cord magnetic resonance imaging with specific protocol for demyelination, including T1, T2, FLAIR sequences and T1 with paramagnetic contrast. Assess presence, location, and characteristics of lesions according to McDonald criteria for dissemination in space (periventricular, juxtacortical, infratentorial, and spinal lesions).

Cerebrospinal fluid analysis: Although not mandatory in all cases, lumbar puncture can provide valuable information, particularly the presence of oligoclonal bands (absent in serum) and elevated IgG index, supporting the diagnosis of demyelinating inflammatory process.

Evoked potentials: Can demonstrate subclinical dysfunction of neural pathways, contributing to evidence of dissemination in space when imaging findings are limited.

Step 2: Verify specifiers

After confirming the diagnosis of MS, it is important to classify the clinical phenotype, as there are specific subcodes under 8A40:

Relapsing-remitting MS: Characterized by clearly defined relapses with complete or partial recovery and absence of progression between relapses. Represents the most common form of initial presentation.

Primary progressive MS: Continuous progression of disability from onset, without clearly defined relapses. There may be periods of stabilization or minor fluctuations, but without true remissions.

Secondary progressive MS: Initially relapsing-remitting, but evolves to continuous progression of disability, with or without superimposed relapses. The transition may be gradual and retrospectively identified.

Severity: Document the degree of disability using validated scales such as the Expanded Disability Status Scale (EDSS), which ranges from 0 (normal neurological examination) to 10 (death from MS).

Disease activity: Classify whether the disease is active (new relapses or new lesions on magnetic resonance imaging) or inactive, and whether there is progression of disability independent of relapses.

Step 3: Differentiate from other codes

8A41 - Syndromes of isolated demyelination of the central nervous system: Use when there is only a single clinical episode of demyelination without complete fulfillment of dissemination in time criteria. The key difference is that 8A41 represents a single event that may or may not evolve to MS, while 8A40 requires evidence of multiple events or lesions at different evolutionary stages.

8A42 - Acute disseminated encephalomyelitis: Differentiate by the presence of encephalopathy (altered level of consciousness), monophasic course, large and diffuse lesions on magnetic resonance imaging, and clinical context (usually post-infectious). ADEM does not recur, while MS is characterized by multiple events or progression.

8A43 - Neuromyelitis optica: The key difference lies in the presence of anti-aquaporin-4 or anti-MOG antibodies, longitudinally extensive spinal cord lesions, preferential involvement of optic nerves and area postrema, and pattern of brain lesions atypical for MS. Treatment and prognosis are substantially different, making the distinction crucial.

Step 4: Required documentation

For appropriate coding of 8A40, ensure you document:

Date and detailed description of each relapse or neurological symptom
Magnetic resonance imaging results with description of lesions
Cerebrospinal fluid analysis results, if performed
Current clinical phenotype (relapsing-remitting, primary progressive, secondary progressive)
Disability scale (EDSS) and functional status
Disease-modifying treatments used and therapeutic response
Comorbidities and complications related to MS
Justification for exclusion of alternative diagnoses

6. Complete Practical Example

Clinical Case:

A 32-year-old female patient, a teacher, seeks neurological care reporting an episode of decreased vision in the right eye that began three days ago, associated with pain on eye movement. She reports that her vision is "blurred" and with reduced color brightness. She denies fever, headache, or other systemic symptoms.

On directed history, the patient recalls that approximately 18 months ago she experienced an episode of tingling and ascending numbness in the left lower limb, which progressed over the course of a week until reaching the umbilical region, lasting about three weeks and resolving spontaneously. At that time, she did not seek medical care because she considered the symptom "strange but tolerable."

On ophthalmologic examination, she presents with visual acuity of 20/200 in the right eye and 20/20 in the left eye, with a relative afferent pupillary defect on the right. Fundoscopy shows no acute changes. General neurologic examination reveals hyperreflexia in the lower limbs and bilateral Babinski sign, without other objective abnormalities.

Brain and spinal cord magnetic resonance imaging was requested, which demonstrated: multiple ovoid hyperintense lesions on T2/FLAIR in periventricular white matter (seven lesions), three juxtacortical lesions, two infratentorial lesions (pons and middle cerebellar peduncle) and one cervical spinal cord lesion at C4. Two periventricular lesions showed enhancement with paramagnetic contrast, while the others did not enhance, indicating lesions at different evolutionary stages.

Analysis of cerebrospinal fluid revealed: cellularity of 8 cells/mm³ (lymphocytic predominance), proteins of 45 mg/dL, normal glucose, presence of oligoclonal bands absent in paired serum, and elevated IgG index.

Visual evoked potentials confirmed delayed conduction in the right optic nerve. Serologies for HIV, syphilis, hepatitis and anti-aquaporin-4 antibody titers were negative.

Step-by-Step Coding:

Criteria Analysis:

Dissemination in time: Confirmed by two distinct clinical episodes (current optic neuritis and previous sensory myelitis 18 months ago) and by the simultaneous presence of lesions with and without contrast enhancement on magnetic resonance imaging.
Dissemination in space: Confirmed by the presence of lesions in multiple characteristic locations: periventricular (≥1), juxtacortical (≥1), infratentorial (≥1) and spinal (≥1).
Exclusion of alternative diagnoses: Negative serologies, absence of anti-aquaporin-4 antibodies (excluding neuromyelitis optica), clinical presentation incompatible with ADEM (without encephalopathy, multiple events).
Clinical phenotype: Relapsing-remitting multiple sclerosis (two distinct relapses with recovery between them).

Code chosen: 8A40 (Multiple sclerosis)

Complete justification:

The patient fully meets the revised McDonald criteria for the diagnosis of multiple sclerosis. She presents with two temporally separated demyelinating clinical events (sensory myelitis 18 months ago and current optic neuritis), satisfying the criterion for dissemination in time. Magnetic resonance imaging demonstrates lesions in all four characteristic locations required for dissemination in space, in addition to showing lesions at different evolutionary stages (with and without enhancement), reinforcing temporal dissemination. Cerebrospinal fluid analysis with oligoclonal bands specific to the central nervous system supports the diagnosis of inflammatory demyelinating process. Alternative diagnoses were appropriately excluded. The phenotype is relapsing-remitting MS, justifying the use of code 8A40.

Applicable complementary codes:

Code for optic neuritis (current symptom)
Code for spasticity (if present and requiring specific treatment)
Codes for specific complications if present (bladder dysfunction, incapacitating fatigue, etc.)

7. Related Codes and Differentiation

Within the Same Category:

8A41: Isolated demyelinating syndromes of the central nervous system

When to use: Use 8A41 when the patient presents with a first clinical episode of demyelination (such as optic neuritis, transverse myelitis, or brainstem syndrome) that does not fully meet McDonald criteria for MS. For example, a patient with acute optic neuritis and magnetic resonance imaging showing only one or two brain lesions, insufficient for dissemination in space.

Main difference: 8A41 represents a single event or insufficient evidence of dissemination in time and space, whereas 8A40 requires complete MS criteria. Patients with 8A41 have risk of conversion to MS, but at the time of diagnosis do not satisfy complete criteria. This distinction is crucial as it influences decisions about initiating disease-modifying therapy.

8A42: Acute disseminated encephalomyelitis

When to use: Use 8A42 for acute, monophasic demyelinating events, often post-infectious or post-vaccinal, characterized by encephalopathy (altered level of consciousness, confusion, lethargy) and diffuse and large demyelinating lesions on magnetic resonance imaging. It is more common in children.

Main difference: ADEM is monophasic (does not recur), presents with prominent encephalopathy, large and poorly defined lesions on imaging, and typical clinical context. MS is characterized by multiple events or progression, without initial encephalopathy, and more characteristic lesions. The temporal evolution clearly distinguishes them: ADEM resolves without recurrences, MS persists or recurs.

8A43: Neuromyelitis optica

When to use: Use 8A43 when there is preferential involvement of optic nerves and spinal cord, with longitudinally extensive spinal cord lesions (≥3 vertebral segments), presence of anti-aquaporin-4 or anti-MOG antibodies, and pattern of brain lesions atypical for MS (when present, they are located in the postrema area, hypothalamus, periventricular).

Main difference: NMO/NMOSD has distinct pathophysiology (antibodies against aquaporin-4 or MOG), different pattern of involvement (preference for optic nerves and spinal cord, with extensive spinal cord lesions), and response to specific treatments different from MS. Many treatments effective for MS may worsen NMO, making this distinction critical.

Differential Diagnoses:

Cerebrovascular diseases: Can produce white matter lesions, but generally in older patients with vascular risk factors, different distribution of lesions (more in small vessel territory, less periventricular ovoid), and absence of enhancement or typical MS progression.

Migraine: Can cause nonspecific white matter lesions, but without the typical morphological characteristics of MS (ovoid lesions perpendicular to ventricles, corpus callosum involvement), without enhancement, and without correlation with persistent focal neurological symptoms.

Central nervous system vasculitis: Can cause multifocal lesions, but generally with systemic symptoms, elevated inflammatory markers, different pattern of lesions, and possible involvement of medium and large vessels visible on angiography.

Sarcoidosis: Can involve the central nervous system with lesions similar to MS, but generally with systemic involvement (pulmonary, cutaneous, ocular), characteristic pattern of leptomeningeal enhancement, and histological confirmation of non-caseating granulomas.

8. Differences with ICD-10

Equivalent ICD-10 code: G35 (Multiple sclerosis)

The transition from ICD-10 to ICD-11 brought significant changes in the coding of multiple sclerosis:

Expanded hierarchical structure: In ICD-10, G35 was a single code without specific official subdivisions for different clinical phenotypes. ICD-11 introduces a hierarchical structure under 8A40, allowing more specific coding of subtypes (relapsing-remitting, primary progressive, secondary progressive), facilitating epidemiological research and effectiveness analyses of treatments specific to each phenotype.

Clearer separation of related conditions: ICD-11 establishes more precise distinction between MS (8A40), isolated demyelination syndromes (8A41), ADEM (8A42), and optic neuromyelitis (8A43). In ICD-10, some of these conditions were coded under G36 (Other acute disseminated demyelinations) or G37 (Other demyelinating diseases of the central nervous system), without clear differentiation.

Incorporation of updated diagnostic criteria: The ICD-11 definition for 8A40 reflects the revised McDonald criteria, emphasizing the importance of integrated clinical and paraclinical data, and recognizing the dynamic nature of phenotypes. ICD-10 did not explicitly incorporate these modern criteria.

Practical impact: The transition requires updating health information systems, training of coding professionals, and review of clinical protocols that reference ICD-10 codes. For purposes of comparing historical data, it is necessary to establish equivalence tables between G35 and 8A40, recognizing that the correspondence is not always perfect due to ICD-11's more detailed subdivisions. Reimbursement systems and medication authorization need to be updated to recognize the new codes, ensuring that patients do not face interruptions in access to treatments due to coding changes.

9. Frequently Asked Questions

1. How is multiple sclerosis diagnosed?

The diagnosis of MS is based on clinical and paraclinical criteria, primarily the revised McDonald criteria. It requires demonstration of dissemination of demyelinating lesions in space (multiple locations in the central nervous system) and in time (events at different moments). Magnetic resonance imaging is fundamental, identifying characteristic lesions in periventricular white matter, juxtacortical, infratentorial, and spinal cord locations. Analysis of cerebrospinal fluid, showing oligoclonal bands specific to the central nervous system, supports the diagnosis. Evoked potentials can demonstrate subclinical dysfunction of neural pathways. Crucially, diagnosis requires exclusion of alternative conditions that may mimic MS, through serologies, measurement of specific antibodies, and careful clinical evaluation.

2. Is treatment available in public health systems?

The availability of disease-modifying treatments for MS varies according to the health system and geographic region. Many public health systems provide access to MS medications, recognizing the disabling nature of the disease and the benefit of early intervention. However, access may be subject to specific eligibility criteria, established clinical protocols, and availability of specific medications. First-line treatments, such as interferons and glatiramer acetate, are generally more widely available, while newer and high-cost therapies may require additional justifications, failure of previous treatments, or specific disease characteristics. Patients should consult neurologists familiar with local protocols to properly navigate access to treatments.

3. How long does treatment last?

The treatment of multiple sclerosis is typically long-term, often for life. Disease-modifying therapies are generally maintained indefinitely as long as they are effective (controlling relapses and progression) and well tolerated. Interruptions may be considered in specific situations: patients with stable disease for many years without clinical or radiological activity, development of significant adverse effects, transition to non-inflammatory phase of disease (secondary progressive MS without relapses), or individualized decisions based on advanced age and comorbidities. However, discontinuation should be carefully discussed with the neurologist, as there may be risk of disease reactivation. Beyond disease-modifying therapies, symptomatic treatments (for spasticity, fatigue, pain, bladder dysfunction) and rehabilitation are often necessary continuously.

4. Can this code be used in medical certificates?

Yes, code 8A40 can and should be used in medical certificates when appropriate. Certificates for work leave due to acute relapses, disease complications, or need for intensive treatment should include the ICD-11 code 8A40. Adequate documentation is essential to justify the need for leave, especially considering that MS is a chronic condition with periods of exacerbation and remission. For prolonged or permanent leave, correct coding is crucial for disability benefit approval processes. However, it is important that the certificate also clearly describes specific functional limitations and how the disease impacts work capacity, not limited to the diagnostic code alone.

5. Can I have MS even without visible symptoms?

Yes, it is possible to have multiple sclerosis with minimal or externally non-apparent symptoms, especially in early stages or during periods of remission. Many MS symptoms, such as fatigue, sensory changes, mild cognitive dysfunction, or subtle visual symptoms, are not visible to external observers. Furthermore, magnetic resonance imaging may show demyelinating lesions before the development of corresponding clinical symptoms ("silent" lesions). However, for formal MS diagnosis, there must be objective evidence of central nervous system dysfunction, whether through clinical symptoms, findings on neurological examination, or characteristic lesions on imaging studies. The absence of visible symptoms does not invalidate the diagnosis when appropriate criteria are satisfied.

6. Is multiple sclerosis hereditary?

Multiple sclerosis is not a hereditary disease in the classical sense (does not follow Mendelian inheritance pattern), but there is a genetic component that influences susceptibility. First-degree relatives of people with MS have increased risk of developing the disease compared to the general population, but the absolute risk remains relatively low (approximately 2-5% for siblings and children of people with MS). Twin studies show concordance of approximately 25-30% in identical twins, confirming genetic influence, but also demonstrating that environmental factors are crucial (if it were purely genetic, concordance would be close to 100%). Multiple susceptibility genes have been identified, with the HLA system being the most strongly associated. Important environmental factors include vitamin D levels, Epstein-Barr virus infection, smoking, and geographic latitude.

7. Can women with MS become pregnant?

Yes, women with multiple sclerosis can become pregnant and have successful pregnancies. Pregnancy does not increase the long-term risk of MS progression, and many women experience a reduction in relapse frequency during pregnancy, particularly in the third trimester, possibly due to physiological immunological changes. However, there is increased risk of relapses in the first three to six months postpartum. Preconception planning is essential, as many disease-modifying therapies are contraindicated during pregnancy and must be discontinued before conception. Some newer therapies may be continued during pregnancy, and decisions should be individualized considering disease activity and specific risks of each medication. Joint follow-up between neurologist and obstetrician is fundamental to optimize maternal and fetal outcomes.

8. Does multiple sclerosis always lead to a wheelchair?

No, multiple sclerosis does not inevitably lead to a wheelchair. With currently available disease-modifying treatments, the natural history of MS has changed significantly in recent decades. Many patients maintain independent ambulation capacity for many years or decades after diagnosis. The prognosis varies considerably among individuals, depending on factors such as clinical phenotype (relapsing-remitting has better prognosis than progressive forms), age of onset (younger onset is generally associated with better long-term prognosis), treatment response, and specific disease characteristics. Approximately 15-20% of patients have a benign course with minimal disability after 20 years. Early intervention with effective disease-modifying therapies, aggressive treatment of relapses, appropriate rehabilitation, and management of complications are fundamental to optimize long-term functional outcomes.

Conclusion:

Appropriate coding of multiple sclerosis using ICD-11 code 8A40 requires comprehensive understanding of diagnostic criteria, recognition of different clinical phenotypes, and ability to differentiate MS from related but distinct conditions. This article provided detailed guidance on when to use code 8A40, exclusion situations, step-by-step coding process, and practical examples for clinical application. The transition from ICD-10 to ICD-11 brought greater specificity and alignment with contemporary diagnostic criteria, benefiting both clinical practice and epidemiological research. Healthcare professionals should familiarize themselves with these updates to ensure accurate documentation, appropriate access to treatments, and optimized care for patients living with multiple sclerosis.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Multiple sclerosis

Compartilhar